Clinical Trials Logo

Headache clinical trials

View clinical trials related to Headache.

Filter by:

NCT ID: NCT06004388 Active, not recruiting - Migraine Clinical Trials

Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

Start date: July 21, 2023
Phase: Phase 3
Study type: Interventional

Randomized study of two digital therapeutics for the prevention of episodic migraine in patients currently receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy

NCT ID: NCT05999201 Not yet recruiting - Clinical trials for Tension-Type Headache

Effect of Craniocervical Neural Mobilization on Quality of Life in Patients With Primary Tension Headache

TTH
Start date: August 20, 2023
Phase: N/A
Study type: Interventional

this study will be conducted to investigate the effect of craniocervical neural mobilization on quality of life in patients with primary tension headache.

NCT ID: NCT05990153 Recruiting - Headache Clinical Trials

Evaluation of the Efficacy of Manual Therapy, Therapeutic Exercise and the Two Modalities Combined in Pain Reduction in Patients With Headache

Start date: April 5, 2023
Phase: N/A
Study type: Interventional

The study aims to evaluate which is the best approach for the non-pharmacological treatment of patients with different types of primary headaches (tension-type headache (TTC), trigeminal autonomic headache (TACs) and migraine) or cervicogenic headache by comparing three methods of intervention to control treatment (drug therapy): therapeutic exercise (TE), myofascial release + TE, and Mulligan's manual therapy + TE. The efficacy will be evaluated in terms of reduction of headache episodes, pain intensity and its duration.

NCT ID: NCT05984719 Active, not recruiting - Clinical trials for New Daily Persistent Headache

New Daily Persistent Headache Survey

NDPH
Start date: June 19, 2023
Phase:
Study type: Observational

Purpose: to explore headache characteristics and treatment effects of patient with new daily persistent headache (NDPH) through an online survey. Research design: Online survey of patients with new daily persistent headache. Risks: Risks include a breach of confidentiality as well as fatigue from taking the survey online. Importance of knowledge that may recently be expected to result: The study aims to discover new information in a very understudied disease. This information could, in future studies, help change the diagnostic criteria or lead to new treatment options.

NCT ID: NCT05983354 Not yet recruiting - Clinical trials for Acute Migraine Headache

Oral Medications for the Management of Acute Migraine Headache in the Emergency Department

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The goal of this pilot randomized control trial is to assess the feasibility of our patient recruitment and data collection strategy ahead of a full scale RCT investigating the efficacy of oral v. parenteral medications in the management of acute migraine headaches in the emergency department. Patients will be randomly assigned to receive either (A) standard medical therapy for the treatment of acute migraine headache (metoclopramide and ketorolac IV) and oral placebo or (B) oral metoclopramide and ibuprofen with normal saline IV. Primary outcome measures are recruitment rate and improvement in pain score at 60 minutes from medication administration.

NCT ID: NCT05978258 Not yet recruiting - Cluster Headache Clinical Trials

A Close Examination of Patient Experiences in Cluster Headache Clinical Research

Start date: August 2024
Phase:
Study type: Observational

Historically, participation in clinical studies is highly skewed towards particular demographic groups of people. This research will invite several participants to gather a wide range of information on clinical trial experiences for cluster headache patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of cluster headache. The data collected from this study will help improve future outcomes for all cluster headache patients as well as those in under-represented demographic groups.

NCT ID: NCT05977361 Not yet recruiting - Clinical trials for Post-Dural Puncture Headache

Intrathecal Catheter Placement Versus Resiting Epidural Catheter After Dural Puncture in Obstetric Patients

ItaREVI
Start date: April 26, 2024
Phase: N/A
Study type: Interventional

Epidural anesthesia represents the most popular method for pain relief during labour. Unintentional dural puncture (UDP) occurs in 0.4-1.5% of labour epidural analgesia, representing therefore the most common complication. Up to 80% of patients with a UDP may develop a post-dural puncture headache (PDPH). When a UDP occurs, two possible strategies have been proposed in order to ensure analgesia during labour: either resiting the epidural catheter in a different intervertebral space, or inserting an intrathecal catheter. Both strategies proved to equally provide analgesia during labour, but their relative contribution in preventing PDPH is still not known. The primary aim of this multicenter randomized controlled trial is therefore to compare these two strategies in the occurrence of PDPH at 24 hours from the UDP.

NCT ID: NCT05972382 Recruiting - Clinical trials for Cervicogenic Headache

Associations Between Neck Muscle Fatigue, Joint Position Sense, and Headache in Cervicogenic Headache

Start date: July 28, 2023
Phase:
Study type: Observational

This research study aims to better understand the relationships between neck muscle function, neck joint position sense, and headache pain and disability in people with chronic cervicogenic headache. Cervicogenic headache is headache originating from the neck area. Participants will fill out questionnaires about their headache pain and ability to do daily activities. They will also do tests to measure neck muscle fatigue and neck joint position sense. Researchers will analyze if those with more neck muscle fatigue and poorer joint position sense have worse headache pain and disability. The results may improve understanding of cervical spine factors related to cervicogenic headache. This could help guide more targeted treatment approaches.

NCT ID: NCT05969119 Completed - Clinical trials for Postdural Puncture Headache

Addition of Pyridostigmine to Conventional Management of Postdural Puncture Headache

Start date: July 25, 2023
Phase: Phase 4
Study type: Interventional

Postdural puncture headache (PDPH) is a major complication of neuraxial anesthesia that can occur following spinal anesthesia and with inadvertent Dural puncture during epidural anesthesia. The presence of Pyridostigmine in CSF would be expected to increase the level of acetylcholine in CSF and subsequently in the brain through inhibition of cholinesterase. The increased level of acetylcholine would produce cerebral vasoconstriction.

NCT ID: NCT05967442 Completed - Migraine Clinical Trials

Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines

MAGraine
Start date: August 23, 2019
Phase: Phase 3
Study type: Interventional

This investigation describes a proposed clinical trial that will evaluate the relative efficacy of intravenous magnesium sulfate for the treatment of migraine compared to intravenous metoclopramide (Reglan) and intravenous prochlorperazine (Compazine) in the treatment of acute headache and migraine in adult patients. The ultimate objective will be clinical application of these drugs in the emergency department for the treatment of acute headache and migraine. The two phenothiazines (metoclopramide and prochlorperazine) have been routinely utilized in the treatment of acute headache and migraine in the emergency department setting. Per the 2017 American Headache Society guidelines, both intravenous metoclopramide and intravenous procholorperazine are recommended as "clinicians should offer" agents with level B evidence. Of note, there are no agents with level A evidence purported by this guideline for acute management of migraine. The same guideline offers "no recommendation can be made regarding the role of intravenous magnesium for adults who present to the ED with acute migraine. However intravenous magnesium may be of benefit to patients who present with migraine with aura." Multiple trials have evaluated intravenous magnesium's safety and efficacy in the management of acute migraine. These have demonstrated the tolerability of intravenous magnesium on a with breadth of patients. Most commonly the primary adverse event was flushing which self-resolved. No cases of hypotension were reported. None of these study agents have been withdrawn from the market.